Close
ACHEMA MIDDLE EAST 2026

Pharmacovigilance & Risk Management for Biosimilars: Unique Challenges & Possible Solutions

AI Summary

Biological medicines have made substantial contributions to the treatment of many chronic and serious diseases and are expected to provide significant therapeutic benefits to many patients who would otherwise have had limited treatment options.

Increasingly aging populations and this growing burden of chronic diseases have put tremendous pressure on healthcare systems all over the world, increasing demand for cost effective medicines.

This has opened up huge opportunities for follow-on biologics, or biosimilars, to enter the market and serve the needs of patients all over the world in a cost effective manner.

Click here to Download the White paper

Senior pharmaceutical decision - makers don’t consume every piece of content. They have sources they trust. Pharma Advancement is one of them.

Reaching this audience means appearing where they already are — inside trusted editorial that covers the full pharmaceutical and life sciences value chain. Our 2026 Media Pack shows you where to be seen:

Magazine & Digital

Where pharmaceutical decision - makers go to understand what’s coming next. Your brand belongs in that conversation.

Insights & Reports

The analysis and research the sector references when it matters most. Being part of it positions you differently.

Brand Authority

The companies that show up consistently in trusted editorial don’t need to explain who they are. They already are.

SUBSCRIBE OUR NEWSLETTER

WHITE PAPERS

RELATED ARTICLES